19 January 2024
19 January 2024
The study is designed to evaluate OBT076 both as a monotherapy and along with Agenus' balstilimab.
The trial is designed to assess the safety, efficacy, and tolerability of HT-001 in treating EGFRI-induced skin toxicity.
A key aspect of the trial is the pharmacodynamic assessment of EVO756's impact on mast cell degranulation.
The study will explore the effects of a single dose of K8 in previously untreated patients with DME.
The study found the average cost of adjuvant radiation therapy to be $60,693 per person, with a total of $1.4bn in all Medicare patients.
The World Economic Forum's AI Governance Alliance has explored the potential risks of advanced AI in three new reports.
Onward Medical is already in the final design stages for a planned pivotal trial to support regulatory submission.
The company plans to enrol 375 subjects in two clinical trials in the US and the UK by the end of 2024.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
